Dr. Sanchari Sinha Dutta

Feature Writer

B.Sc. Physiology, M.Sc. Physiology, Ph.D. Physiology

Dr. Sanchari Sinha Dutta is a science communicator who believes in spreading the power of science in every corner of the world.

Since she was very young, Dr. Dutta was passionate about the world of science and making it accessible to all. During her time at school, Dr. Dutta particularly enjoyed taking part in biology experiments in the laboratory. The inner workings and diversity of the human body used to surprise her every day and eventually inspired her to become a biologist.

In order to learn more about the subject, Sanchari decided to take biology as her main subject at university and gained Bachelor of Science (B.Sc.) and Master of Science (M.Sc.) degrees in human physiology from the University of Calcutta, India.

This was followed by a Ph.D., also in physiology. During her tenure (2004 – 2010), she received the ‘Surg. Rear Admiral M.S. Malhotra Research Prize’ for best publication from the Defence Institute of Physiology and Allied Sciences, India.

Her thirst for knowledge and dream to be a science writer were always abreast throughout her academic tenure. However, instead of starting her career as a writer straight away, Sanchari decided to further her knowledge of the molecular biology of the human body and carried out postdoctoral research for 6 years after her Ph.D.

During this period, Dr. Dutta received ‘Dean of Faculty fellowship of Weizmann Institute of Science, Israel’ and ‘PBC fellowship for outstanding post-doctoral researchers from China and India in Israeli universities’.

Alongside bench work, she authored more than 10 original research articles, all published in renowned international journals.

In 2016, she started working with a leading medical communication company and formally became a freelance science writer. Since then, she has engaged in writing a wide variety of scientific articles, including original research articles, review articles, science discoveries, popular science articles, and healthcare articles. Her first review article as a science writer was recently published in the journal ‘Oxidative Medicine and Cellular Longevity’.

Her work with News Medical offers a great platform for a wide range of audience to learn about the science behind good health.

See less

Articles from Sanchari Sinha Dutta

Testing unavailability may influence public behaviors and facilitate SARS-CoV-2 transmission

A team of scientists from the University of California, Los Angeles, USA, recently conducted a survey investigating the association between availability of testing facilities and COVID-19-related behavioral aspects. Their findings reveal that testing unavailability independently influences certain COVID-19-related behaviors that may increase the risk of SARS-CoV-2 transmission.

26 Mar 2021

Identification of specific anti-SARS-CoV-2 antibodies with cross-neutralization potency

A team of scientists from the USA and Canada recently characterized the cross-neutralizing potency of anti-SARS-CoV-2 antibodies isolated from COVID-19 patients. The findings reveal that some of the isolated antibodies targeting the spike RBD and the S2 subunit are capable of cross-neutralizing other members of the human beta-coronavirus family.

25 Mar 2021

Long-term complications are common among COVID-19 recovered individuals

A team of scientists from the United Kingdom has recently conducted a multicenter, prospective cohort study to investigate long-term consequences of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

24 Mar 2021

A new COVID-19 candidate vaccine induces robust humoral and cellular immune responses in mice

A Korea-based company EyeGene Inc. has recently developed a liposome-based mRNA candidate vaccine against COVID-19, which contains full-length spike protein of the European variant (D614G) of SARS-CoV-2 as a vaccine antigen.

23 Mar 2021

SARS-CoV-2 variants develop resistance against type I interferons

A study conducted at the University of Colorado and National Institutes of Health, USA, has revealed that the resistance developed by newly emerging variants of SARS-CoV-2 against host interferon responses could serve as a potential driving force for viral evolution.

22 Mar 2021

Quantum dot-based affinity biosensors in microfluidic systems offer an alternative SARS-CoV-2 diagnostics platform

In a new study published in Emergent Materials, researchers show how microfluidic systems integrated with quantum dot-based affinity biosensors can serve as a valuable platform to rapidly and accurately diagnose SARS-CoV-2 infection.

17 Mar 2021

SARS-CoV-2 Brazilian variant may potentially escape T cell-mediated host immune responses

A team of scientists from Brazil recently explored the abilities of the UK, South African, and Brazilian variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to evade host CD8+ T cell responses induced by natural infection or vaccination. The findings reveal reduced antigenic coverage for the P.2 Brazilian lineage, indicating its ability to evade SARS-CoV-2-induced T cell responses.

16 Mar 2021

SARS-CoV-2 UK variant could be more lethal than others

A new study has assessed the mortality risk of patients infected with the newly emerged UK variant (Lineage B.1.1.7) of SARS-CoV-2. The findings reveal that compared to the previously circulating SARS-CoV-2 variants, the UK variant significantly increases the risk of mortality in a relatively low-risk community population.

15 Mar 2021

Study identifies three novel binding receptors for SARS-CoV-2

A team of scientists from the United Kingdom recently conducted a large-scale screening of several membrane-bound and soluble host cell receptors to identify novel binding partners for SARS-CoV-2. They have identified three novel receptors expressed on the human cell membrane; of which, one binds to SARS-CoV-2 spike with similar affinity as angiotensin-converting enzyme 2 (ACE2).

12 Mar 2021

Could an “ACE2 Triple Decoy” be an alternative approach to neutralizing SARS-CoV-2?

A team of scientists from the USA recently developed a recombinant “Angiotensin converting enzyme 2 (ACE2) Triple Decoy” that can trap SARS-CoV-2 and prevent its propagation inside the host cell.

11 Mar 2021